Haemonetics (HAE)
(Delayed Data from NYSE)
$91.42 USD
-0.16 (-0.17%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $91.41 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HAE 91.42 -0.16(-0.17%)
Will HAE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HAE
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
HAE vs. BSX: Which Stock Is the Better Value Option?
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings
Other News for HAE
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
AMD initiated, Paramount downgraded: Wall Street's top analyst calls